Sandbox
Swiss pharmaceutical giant Roche is moving to sell its former manufacturing site in Clarecastle, Co Clare, with commercial real estate specialists Cushman & Wakefield appointed to lead a targeted national and international marketing campaign targeting an expected price of approximately €4 million.
The 88-acre (36-hectare) site - described by the selling agents as "one of the most compelling industrial opportunities currently available in the west of Ireland" - has undergone an extensive decommissioning process that has already cost in excess of €150 million, according to accounts published by Roche last year.
A Five-Decade Legacy in Irish Pharmaceutical Manufacturing
The Clarecastle facility has deep roots in Ireland's pharmaceutical sector. It was originally established in 1974 as Syntex Ireland, becoming one of the earliest pharmaceutical manufacturing operations in the midwest of Ireland. When the Roche Group acquired the site in 1994, it was integrated into Roche's global pharmaceutical manufacturing network, playing a significant role in Ireland's growing position as a global hub for pharma production.
Following a strategic decision in 2015 to exit the Clarecastle operation, the facility continued production in a wind-down capacity. Final manufacturing was completed in November 2019, and pharmaceutical operations formally ceased in March 2020. At the time, Roche was unable to secure a buyer for the facility in its operational state, and subsequently embarked on a comprehensive decommissioning and environmental remediation programme - a project that has now cost over €150 million.
Site Details and Infrastructure
The site's scale and existing infrastructure give it significant competitive advantages over greenfield alternatives in the region. Key utilities already in place include:
- A dedicated wastewater treatment plant
- On-site gas supply connection
- Established road network with arterial access
- An electrical substation and distribution network
The property is zoned for mixed use, providing flexibility for a range of industrial, enterprise, and campus-style developments. Critically, it will be brought to market on a phased basis - with an initial tranche of approximately 20 hectares (45 acres) expected to be available by late 2027, as the ongoing remediation work is completed on the remaining sections of the site.
Who Is Being Targeted?
Cushman & Wakefield say they will pursue a targeted national and international investor campaign across key growth sectors seeking a strategic location for expansion in Ireland. The site is expected to attract particular interest from companies seeking access to:
- Ireland's established multi-sectoral industrial ecosystem
- A highly-skilled workforce with deep experience in pharmaceutical and precision manufacturing
- A supportive FDI-friendly business environment, backed by IDA Ireland and Clare County Council
- Strong infrastructure connectivity to Shannon Airport and the Atlantic Economic Corridor
The estate agents confirmed that the sale objective includes a "clear objective of identifying an investor capable of delivering sustainable employment and long-term economic benefit to the region."
Reactions and Outlook
Commenting on the opportunity, Patricia Staunton of Cushman & Wakefield said: "This is a unique opportunity to reposition a strategically located site with significant scale and infrastructure, capable of accommodating high-value enterprise."
"We are working closely with Roche to ensure that the marketing process delivers not only a successful transaction, but also a meaningful long-term impact in terms of employment, investment, and regional development," she added.
For the Clarecastle community and Co Clare more broadly, the sale represents a pivotal moment. The site's remediation - one of the largest such programmes undertaken at a former pharma facility in Ireland - has removed the environmental liabilities that previously deterred buyers, and the phased release structure is designed to give prospective investors certainty over delivery timelines.
Context: Ireland's Pharma Footprint
The Roche Clarecastle sale comes at a time of considerable dynamism in Ireland's life sciences property market. Ireland remains one of the world's premier pharmaceutical manufacturing destinations, with nine of the top ten global pharma companies operating production facilities here. The availability of a large, infrastructure-ready site in the midwest, near Shannon's well-established industrial base, is likely to draw significant interest from both domestic developers and international life science companies seeking European manufacturing footholds.
Expressions of interest are being managed by Cushman & Wakefield on behalf of Roche Ireland Limited.
